• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    10/13/23 4:30:23 PM ET
    $AVCO
    Building operators
    Real Estate
    Get the next $AVCO alert in real time by email
    0001630212 false 0001630212 2023-10-12 2023-10-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 12, 2023

     

    AVALON GLOBOCARE CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38728   47-1685128
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    4400 Route 9 South, Suite 3100

    Freehold, NJ 07728

    (Address of principal executive offices)

     

    (732) 780-4400

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report.)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ALBT   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    Convertible Note Financing

     

    On October 9, 2023, AVALON GLOBOCARE CORP. (the “Company”) entered into securities purchase agreements (the “Securities Purchase Agreements”) with Mast Hill Fund, L.P. (“Mast Hill”) and Firstfire Global Opportunities Fund, LLC. (“Firstfire”) for the issuance of 13% senior secured promissory notes in the aggregate principal amount of $700,000.00 (collectively the “Notes”) convertible into shares of common stock, par value $0.0001 per share, of the Company, as well as the issuance of up to 70,000 shares of common stock as a commitment fee and warrants for the purchase of up to 105,000 shares of Common Stock at an initial price per share of $2.50 and common share purchase warrants for the purchase of up to 87,500 shares of Common Stock at an initial price per share of $1.80 (collectively, the “October 2023 Warrants”). The Company and its subsidiaries have entered into that certain security agreements (the “Security Agreements”), creating a security interest in certain property of the Company and its subsidiaries to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Notes. The transaction closed on October 11, 2023(the “Closing Dates”).

     

    Mast Hill acquired the Notes with principal amount of $350,000.00 and paid the purchase price of $332,500.00 after an original issue discount of $17,500.00 On the same Closing Date, the Company issued (i) a warrant to purchase 52,500 shares of common stock with an exercise price of $2.50 exercisable until the five-year anniversary of the Closing Date, (ii) a warrant to purchase 43,750 shares of common stock with an exercise price of $1.80 exercisable until the five-year anniversary of the Closing Date, which warrant shall be cancelled and extinguished against payment of the Notes, and (iii) 35,000 shares of common stock to Mast Hill as additional consideration for the purchase of the Note, which were earned in full as of the Closing Date. On the Closing Date, the Company delivered such duly executed Notes, warrants and common stock to Mast Hill against delivery of such purchase price.

     

    Firstfire acquired the Notes with principal amount of $350,000.00 and paid the purchase price of $332,500.00 after an original issue discount of $17,500.00 On the same Closing Date, the Company issued (i) a warrant to purchase 52,500 shares of common stock with an exercise price of $2.50 exercisable until the five-year anniversary of the Closing Date, (ii) a warrant to purchase 43,750 shares of common stock with an exercise price of $1.80 exercisable until the five-year anniversary of the Closing Date, which warrant shall be cancelled and extinguished against payment of the Notes, and (iii) 35,00] shares of common stock to Firstfire as additional consideration for the purchase of the Note, which were earned in full as of the Closing Date. On the Closing Date, the Company delivered such duly executed Notes, warrants and common stock to Firstfire against delivery of such purchase price.

     

    The Securities Purchase Agreements contains customary representations and warranties and agreements and obligations of the parties. The proceeds of this Note financing will be used for general corporate purposes. The foregoing description of the Securities Purchase Agreement, the Security Agreement, the Note and the Warrants is qualified in its entirety by reference to the full text of such agreements, copies of which are filed as Exhibits 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9 and 10.10, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

     

    Mortgage and Security Agreement

     

    On October 9, 2023, the Company entered into mortgage and security agreement (the “Mortgage and Security Agreement”) with Mast Hill and Firstfire (the “Secured Parties”) to secure the payment performance and obligation under the Notes. The Company is indebted to the Secured Part in the combined principal sum of Seven Hundred Thousand and 00/100 ($700,000.00) Dollars, which sum, together with interest, is to be paid according to the Notes.

     

    The foregoing description of the Mortgage and Security Agreement is qualified in its entirety by reference to the full text of such agreements, copies of which are filed as Exhibits 10.11, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

     

     

     

    Item 3.02. Unregistered Sales of Equity Securities.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

    The securities described above have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state, and were offered and sold in reliance on the exemption from registration under the Securities Act afforded by Section 4(a)(2) thereof.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description.
    10.1   Securities Purchase Agreement, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P.
    10.2   Security Agreement, dated  October 9, 2023, among Avalon Globocare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Laboratory Services MSO, LLC, Genexosome Technologies Inc., International Exosome Association LLC and Mast Hill Fund, L.P.
    10.3   Senior Secured Promissory Note, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P.
    10.4   First Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P.
    10.5   Second Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Mast Hill Fund, L.P.
    10.6   Securities Purchase Agreement, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC.
    10.7   Security Agreement, dated October 9, 2023, among Avalon Globocare Corp., Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., Avalon RT 9 Properties, LLC, Avactis Biosciences, Inc., Laboratory Services MSO, LLC, Genexosome Technologies Inc., International Exosome Association LLC and Firstfire Global Opportunities Fund, LLC.
    10.8   Senior Secured Promissory Note, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC.
    10.9   First Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC.
    10.10   Second Warrant, dated October 9, 2023, between Avalon Globocare Corp. and Firstfire Global Opportunities Fund, LLC.
    10.11   Mortgage and Security Agreement, dated October 9, 2023, between Avalon Globocare Corp., Mast Hill Fund, L.P and Firstfire Global Opportunities Fund, LLC.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

      

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AVALON GLOBOCARE CORP.
         
    Date: October 13, 2023 By: /s/ Luisa Ingargiola
      Name: Luisa Ingargiola
      Title: Chief Financial Officer

     

     

     

    Get the next $AVCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AVCO
    SEC Filings

    View All

    Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Avalon GloboCare Corp. (0001630212) (Filer)

    11/22/23 4:49:04 PM ET
    $AVCO
    Building operators
    Real Estate

    SEC Form 10-Q filed by Avalon GloboCare Corp.

    10-Q - Avalon GloboCare Corp. (0001630212) (Filer)

    11/14/23 4:30:53 PM ET
    $AVCO
    Building operators
    Real Estate

    Avalon GloboCare Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Avalon GloboCare Corp. (0001630212) (Filer)

    11/9/23 4:30:46 PM ET
    $AVCO
    Building operators
    Real Estate

    $AVCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"

    Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,

    11/9/22 4:00:00 PM ET
    $AVCO
    Building operators
    Real Estate

    Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

    Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and

    11/8/22 9:10:00 AM ET
    $AVCO
    Building operators
    Real Estate

    Avalon Globocare to Present at the LD Micro Main Event XV on October 26th

    Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings

    10/19/22 9:00:00 AM ET
    $AVCO
    Building operators
    Real Estate

    $AVCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tauzin W J

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    3/9/23 11:12:55 AM ET
    $AVCO
    Building operators
    Real Estate

    SEC Form 4 filed by Sanders Steven Andrew

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    3/9/23 11:11:22 AM ET
    $AVCO
    Building operators
    Real Estate

    SEC Form 4 filed by Stilley William B. Iii

    4 - Avalon GloboCare Corp. (0001630212) (Issuer)

    3/8/23 4:45:24 PM ET
    $AVCO
    Building operators
    Real Estate

    $AVCO
    Leadership Updates

    Live Leadership Updates

    View All

    Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

    Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol

    5/18/22 9:00:00 AM ET
    $AVCO
    Building operators
    Real Estate

    Siyata Mobile Appoints Peter Goldstein as Chairman and Adds Seasoned Public Company Executive Luisa Ingargiola to Board of Directors

    VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to

    2/9/21 10:30:49 AM ET
    $SYTA
    $AVCO
    $SOLO
    Telecommunications Equipment
    Telecommunications
    Building operators
    Real Estate

    $AVCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Avalon GloboCare Corp. (Amendment)

    SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)

    1/24/24 8:35:42 PM ET
    $AVCO
    Building operators
    Real Estate